Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) Return on Sales (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Return on Sales for 8 consecutive years, with 4.04% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales fell 272.0% year-over-year to 4.04%, compared with a TTM value of 0.8% through Dec 2025, down 27.0%, and an annual FY2025 reading of 0.8%, down 27.0% over the prior year.
  • Return on Sales was 4.04% for Q4 2025 at Arcturus Therapeutics Holdings, down from 0.78% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.74% in Q4 2022 and bottomed at 27.11% in Q1 2021.
  • Average Return on Sales over 5 years is 5.41%, with a median of 0.79% recorded in 2022.
  • The sharpest move saw Return on Sales tumbled -2354bps in 2021, then soared 2605bps in 2022.
  • Year by year, Return on Sales stood at 6.5% in 2021, then soared by 111bps to 0.74% in 2022, then tumbled by -151bps to 0.38% in 2023, then tumbled by -248bps to 1.32% in 2024, then plummeted by -207bps to 4.04% in 2025.
  • Business Quant data shows Return on Sales for ARCT at 4.04% in Q4 2025, 0.78% in Q3 2025, and 0.32% in Q2 2025.